Cureus

Improvement of stubborn scalp follicle inflammation with tirzepatide: A case report

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Significant symptom improvement and hair regrowth were observed in a man with recalcitrant folliculitis decalvans following tirzepatide treatment.

  • Folliculitis decalvans is characterized by painful, scarring lesions and recurrent flares.
  • Current treatment options for folliculitis decalvans are limited and often ineffective.
  • Tirzepatide, traditionally used for weight management, may provide therapeutic benefits for folliculitis decalvans.
  • The potential benefits of tirzepatide could be linked to its anti-inflammatory and immunomodulatory properties.
  • This case suggests a need for further investigation into GLP-1 receptor agonists for managing refractory dermatologic diseases.

Simplified

Full Text

We can’t show the full text here under this license.
View Full Text ↗

Related papers

Apr '19
Effective Fusidic Acid Treatment for a Patient with Scalp Follicle Inflammation and Hair Loss
cited by 1 paper
case reports
Sep '15
Using targeted radiation therapy to treat folliculitis decalvans
top 30% journal
cited by 9 papers
comparative study
Apr '20
Using light-activated treatment with aminolevulinic acid for a rare scalp inflammation causing hair loss: A case report
top 20% journal
cited by 5 papers
case reports
May '25
A Rare Case of Scalp Follicle Infection and Hair Loss with Summary of Past Reports
case reports
Apr '25
Guidelines for Treating Folliculitis Decalvans from the European Hair Disease Experts
top 5% journal
cited by 5 papers
journal article
Sep '17
Using light-based treatment for a rare scalp inflammation causing hair loss
top 30% journal
cited by 17 papers
case reports
Dec '10
Successful treatment of folliculitis decalvans with specific antibiotics
cited by 32 papers
journal article
Oct '19
Pustular skin plaques on the limbs similar to folliculitis decalvans that do not affect the scalp
top 50% journal
cited by 6 papers
case reports
Oct '20
Hair loss with scarring and inflammation caused by Erlotinib resembling folliculitis decalvans
top 30% journal
cited by 7 papers
case reports
Sep '19
Healing of folliculitis decalvans using medical honey
cited by 2 papers
case reports

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
2 days ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
1 week ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
2 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
3 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
4 weeks ago7 studies
issue #38
Two-thirds of patients kept weight off after stopping GLP-1 drugs
5 weeks ago7 studies
issue #36
Tirzepatide beats semaglutide for weight loss: 8.2% vs 5.8% body weight reduction at 12 months
7 weeks ago7 studies
issue #35
Semaglutide linked to 2.5x higher risk of sudden vision loss
8 weeks ago7 studies
issue #34
Tirzepatide users had 18.4% weight loss vs 11.9% with semaglutide in head-to-head trial
9 weeks ago7 studies
issue #33
Semaglutide linked to 53% lower risk of death in dialysis patients with diabetes
10 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief